Arrowhead - Jetzt kommen die Erfolge - auch an der Börse - 500 Beiträge pro Seite

[mystreet]

keine Nachrichten und jeden Tag + 10%?? (gestern und heute)?

Arrowhead Research Corporation is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

Und gute News gibts jetzt mehrfach:
August 2, 2007
ARROWHEAD SUBSIDIARY UNIDYM SIGNS JOINT DEVELOPMENT AGREEMENT FOR PRINTABLE CONDUCTORS WITH INTERPHASES’ THIN-FILM SOLAR CELLS
PASADENA, Calif.—August 2, 2007--Arrowhead Research Corporation (NASDAQ:ARWR) announced today that its majority-owned subsidiary, Unidym, Inc., has signed a joint development agreement with InterPhases Research, a developer of novel thin-film solar cell technology. The joint development effort will focus on using Unidym's proprietary transparent electrodes with InterPhases’ solar cells made from copper indium selenide (CIS) films. InterPhases’ CIS cells are among the emerging thin-film solar cell technologies that promise to be highly competitive in the overall solar cell product market, which was worth $10.6 billion in 2006 and is expected to grow to $18.5 billion by 2011 according to Solarbuzz, an international solar energy research and consulting company. more...

July 30, 2007
ARROWHEAD SUBSIDIARY SIGNS AGREEMENT TO INTEGRATE ITS PRODUCTS INTO MAJOR DISPLAY MANUFACTURER’S FLAT PANEL DISPLAYS
Pasadena, CA—July 30, 2007--Arrowhead Research (NASDAQ: ARWR) announced today that its majority owned subsidiary, Unidym, has entered an agreement with a major liquid crystal display (LCD) manufacturer to integrate carbon nanotube-based products into display applications. more...

[Scar]

Antwort auf Beitrag Nr.: 31.002.850 von mystreet am 03.08.07 12:53:12

Ist ein super interessanter Wert. Aber hierzulande interessiert sich scheinbar kein einziger dafür.

[Papierhecht]

Antwort auf Beitrag Nr.: 31.184.087 von Scar am 16.08.07 13:43:30

ich bin auch schon seit ca. zwei monaten dabei, beobachte ARWR schon seit ca. zwei Jahren.

[mystreet]

Jetzt die grosse Trendwende! In Berlin werden schon 3,58 € geboten!!

Also deutlich mehr als 50 % plus gegenüber gestern.

[Scar]

Jetzt Spitzeneinstiegskurse, weil scheinbar jeder die Nanotechaktie vergessen hat.
Habe selbst ein bißchen nachgekauft

[Bronto99]

Wenn nicht jetzt, wann dann ?

[Scar]

Nachdem es jetzt erstmal ein wenig hoch ging, wieder bei niedrigsten Umsätzen auf den Tiefststand. Zur Zeit interessiert sich wirklich niemand für Arrowhead.

[schlitzie]

heute mal in die andere Richtung.Lange nicht gesehen !!!!
Bin mal auf Donnerstag gespannt,werde nach Möglichkeit die Sache
verfolgen !!!
Arrowhead's Zeit wird bald kommen !!!!!!!!!!
Gruß Schlitzie (der wieder mit dabei ist)

[schlitzie]

Menlo Park, CA - March 12, 2008 -- Unidym, Inc, a majority-owned
subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR),
announced today that it has entered into a joint development
agreement with Nippon Kayaku, to integrate Unidym's printable
transparent electrodes into Nippon Kayaku's thin film solar cells.
Nippon Kayaku Co. is a diversified Japanese chemical company with
over $1.4B in 2007 sales that is bringing its global development and
manufacturing capabilities to the rapidly developing thin film solar
cell market.

According to Solarbuzz, an international solar energy research and
consulting company, thin-film photovoltaic technologies hold great
promise in the solar market and could contribute strongly to the
industry's expected growth from $10.6 billion in 2006 to $18.5
billion by 2011.

Thin film solar cells require a transparent electrode material for
optimal efficiency, and Unidym's carbon nanotube-based electrodes
could offer substantial benefits over the materials currently in use,
such as indium tin oxide (ITO).

"Unidym's products provide several advantages over ITO for solar cell
manufacturers, including compatibility with high-volume, roll-to-roll
manufacturing techniques, lower materials cost, and enhanced
flexibility," said Art Swift, Unidym's CEO and President. "We expect
our printable electrodes to significantly improve production
economics for innovative solar companies like Nippon Kayaku and
accelerate widespread adoption of solar power."

"Nippon Kayaku is delighted to be working with Unidym to integrate
carbon nanotube-based electrodes into our thin-film solar cells,"
said Mr. T. Inoue, Group Leader of Nippon Kayaku's solar cell
project. "We expect to be a technology leader in this important
segment of the solar power market !

[schlitzie]

PASADENA, Calif.- March 13, 2008 - Arrowhead Research Corporation
(NASDAQ: ARWR) announced today that its majority owned subsidiary,
Calando Pharmaceuticals, a leading siRNA therapeutics company,
submitted an investigational new drug application (IND) to the U.S.
Food and Drug Administration to initiate a Phase I clinical trial
using their lead anti-cancer compound, CALAA-01. Dr. Anzalone will
discuss the IND filing, Calando's clinical plans, and Arrowhead's
other 2008 objectives in a webcast presentation following the Annual
Meeting of Shareholders today at 10:30 AM PT.

"Calando's technology addresses a primary obstacle to the use of
siRNA therapeutics: an effective delivery mechanism," said Dr.
Christopher Anzalone, Arrowhead's Chief Executive Officer. "RNAi
could provide a new way to treat a wide range of human diseases and,
and we believe this is a major step forward for siRNA therapeutics.
To our knowledge, this stands to be the first use of siRNA for
treatment of cancer in humans. This submission represents an
important milestone for Calando and we look forward to starting our
work in the clinic."

The drug candidate is a targeted nanoparticle, comprised of a
proprietary, non-chemically-modified siRNA against the M2 subunit of
ribonucleotide reductase, a clinically-validated cancer target, and
Calando's proprietary siRNA polymer delivery system. The system can
be used to systemically deliver any siRNA.

The Phase I study is an open-label, dose-escalation clinical trial in
patients with non-resectable or metastatic solid tumors. The primary
objectives of the clinical protocol submitted with the IND are to
evaluate the safety and tolerability of CALAA-01 in humans.
Additional objectives include characterization of pharmacokinetics,
evaluation of tumor response, and recommendation of a CALAA-01 dose
for future clinical studies. The trial will be conducted at the UCLA
Jonsson Cancer Center (UCLA) in Los Angeles, California, and the
South Texas Accelerated Research Therapeutics (START) clinic in San
Antonio, Texas.

Dr. Anzalone's presentation, followed by a question and answer
period, will be broadcast live via the Internet and by teleconference
beginning at 10:30 am, and a replay will be available for those who
are unable to attend the live broadcast. Information on how to access
the webcast can be accessed on Arrowhead's website at
http://arrowres.com/meeting2008.html.

[superman]

So habe auch erste Positionen in Arrowhead aufgebaut. Das sieht alles sehr vielversprechend aus und der Dollar ermöglicht auch einen äußerst interessanten Einstieg. Arrowhead scheint sehr gut positioniert für die Zukunft. Frage ist die Finanzierung. Aber hier dürfte weiterhin Interesse von Investoren bestehen Pakete aufzubauen. Im Notfall läuft es auf eine Übernahme hinaus. So ooder so sind die Patente und die Geschäftsmodelle zu interessant um nicht auf eine Art wieterentwickelt zu weren. Zumal das Unternehmen ja auch Vermarktungen für 2008 angekündigt hat.

[Scar]

Ich habe auf Sicht von mehreren Jahren investiert und warte einfach ab.
Irgendwann geht das Teil nach oben. Momentan besteht der Firmenwert zum großen Teil aus Patenten deren tatsächlicher Wert noch gar nicht abschätzbar ist.

[superman]

Unidym Inc. Spins off Ensysce Biosciences Inc. to Pursue Medical Therapeutic Applications of Carbon Nanotubes
Tuesday, March 18, 2008; Posted: 07:00 AM

More Breaking News about ARWR
Arrowhead Unit Requests FDA Permission For Cancer Drug Testing

Calando Files IND for siRNA Nanoparticle Therapeutic in Oncology

Arrowhead's Calando Pharma Submits IND To Begin Phase I Trial Using CALAA-01 - Update

More News for ARWR >>


More Resources for ARWR
Short Term PowerRatings

Long Term PowerRatings

PowerRatings Charts

Quotes & Charts



MENLO PARK, Calif., Mar 18, 2008 (BUSINESS WIRE) -- ARWR | news | PowerRating | PR Charts -- Unidym, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today the formation of a spin-off company, Ensysce Biosciences Inc., that will focus on research into the medical therapeutic applications of carbon nanotubes. Unidym has licensed its extensive nanotechnology patent portfolio to Ensysce for this field of use and in return holds a significant equity position in Ensysce. The inception of Ensysce stems from the final research interests of the late Dr. Richard Smalley, the 1996 Nobel Laureate for Chemistry from Rice University, who was among the pioneers in considering the potential therapeutic applications for carbon nanotubes. Unidym acquired rights to Dr. Smalley's work in carbon nanotechnology through a corporate merger in April of last year.

"Unidym's carbon nanotubes have been widely used in a variety of very promising medical therapeutic research," noted Art Swift, Unidym's president and CEO. "Given the broad applicability of our IP portfolio, it was a natural move to create this spin-off company to, over time, return previously untapped value to Unidym's shareholders by focusing on the application of our intellectual property in medical therapeutics for the systemic treatment of disease, an area that is outside Unidym's core business focus on electronics applications for carbon nanotechnology."

Ensysce will immediately begin working with several of the world's leading chemists and clinicians in the field developing carbon nanotube based therapeutics. One of its first moves is to fund the existing studies using carbon nanotubes for delivery of short interfering RNA (siRNA) using animal models, led by Dr. Bruce Weisman at Rice University and Dr. Garth Powis at the University of Texas M. D. Anderson Cancer Center.

"We have a strong group between our two organizations working in the area of siRNA and are looking forward to working closely with Ensysce," said Dr. Bruce Weisman of Rice University. "In addition to funding our research, Ensysce will provide a clear path to market for our work."

In parallel, Ensysce will immediately fund the research at Stanford University being led by Dr. Hongjie Dai and focused on the delivery of chemotherapy drugs such as taxol and doxorubicin using carbon nanotubes.

"We have made significant progress in delivering chemotherapy drugs into tumor cells and have reached the point where we hope to work with a commercial entity to take our work to the next level," said Dr. Hongjie Dai of Stanford University. "Ensysce's participation in our work could help us progress to animal trials for a solution to substantially increase the efficacy of chemotherapy drugs, while reducing toxicity outside of tumor cells."

Ensysce is also looking at novel ways of using carbon nanotubes to directly treat tumor cells. As a part that research funding program, Ensysce will also fund a team led by Dr. Lon Wilson of Rice University and Dr. Steven Curley of the M. D. Anderson Cancer Center. This team is preparing to move into human trials a cancer therapy that uses carbon nanotubes exposed during treatment to RF radiation.

Terms of the licensing arrangement between Unidym and Ensysce were not announced, but include up-front licensing fees, ongoing royalties, and a significant equity position for Unidym in Ensysce Biosciences. In addition, Unidym will provide contract services to Ensysce, including supplies of research grade nanotubes, back-office and accounting support. Initial operating costs of the new venture, including the funded research at Rice, M.D. Anderson and Stanford, are funded by an angel investor interested in the therapeutic applications of carbon nanotubes. Ensysce expects to put an experienced biotech management team in place after it generates initial animal data from its funded research.

About Unidym:

Unidym (www.unidym.com) is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners. As a result of its recent merger with CNI, Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications.

Unidym is focused on the electronics industry where its initial products include transparent electrodes for touch screens, flat panel displays, solar cells, and solid state lighting; electrodes for fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing an aggressive, cross-industry partnership strategy to capture value from the wide ranging uses of CNTs. Unidym's licensing program, technical expertise and manufacturing facilities can enable partners to rapidly develop CNT solutions for their specific applications.

Unidym is a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR).

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. One can identify these forward-looking statements by the use of the words "expect," "anticipate," "plan," "may," "will," "estimate" and other similar expressions. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Arrowhead Research Corporation's latest Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

SOURCE: Unidym, Inc.

Unidym, Inc. Robert Bismuth, 650-462-1935 [e-mail] or Arrowhead Research Virginia Dadey, 212-541-3707 [e-mail]

[schlitzie]

Was ist denn bei denn Amis los ???Da hatte aber kurz nach Eröffnung, jemand richtig Appetit auf Arrowhead !!!!!!!!
Glück auf
Schlitzie

[schlitzie]

NASDAQ - 1,87% Arrowhead + 9,12 % auf Tageshoch geschlossen.

so kann es weiter gehen !!!!!!!!!!!!!!
Gruß Schlitzie

[Scar]

Antwort auf Beitrag Nr.: 33.746.118 von schlitzie am 28.03.08 06:14:28

krasser Kursverlauf. Jetzt wieder 16% runter.

[Scar]

hat jemand vielleicht mal wieder eine Einschätzung, Analystenbewertung oä über Arrowhead gefunden.
Tut sich nicht viel bei dem Wert.

[zuzi]

Antwort auf Beitrag Nr.: 34.371.512 von Scar am 25.06.08 13:30:39

gestern über 1500000 milli über den tisch .grund?

[Scar]

Schade, jetzt gehts schon wieder runter

11-Aug-2008

Quarterly Report


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains forward-looking statements concerning future events and performance of the Company. When used in this report, the words "intends," "estimates," "anticipates," "believes," "plans," "may," "will," "should," "projects" or "expects" and similar expressions are included to identify forward-looking statements. These forward-looking statements are based on our current expectations and assumptions and many factors could cause our actual results to differ materially from those indicated in these forward-looking statements. You should review carefully the factors identified in this report under the caption "Risk Factors" and in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"). We disclaim any intent to update or announce revisions to any forward-looking statements to reflect actual events or developments. Except as otherwise indicated herein, all dates referred to in this report represent periods or dates fixed with reference to the calendar year, rather than our fiscal year ending September 30. The three-month period ended June 30, 2008, may also be referred to as the third quarter of fiscal 2008.

Overview

Arrowhead is a development stage nanotechnology company commercializing new technologies in the areas of life sciences, electronics and energy. Arrowhead's mission is to build value through the identification, development and commercialization of nanotechnology-related products and applications. The Company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Arrowhead takes a portfolio approach by operating multiple subsidiaries, which allows the pursuit of multiple opportunities and diversifies risk. At June 30, 2008, Arrowhead was operating three majority-owned subsidiaries (the "Subsidiaries"), owned minority positions in two other companies (the "Minority Positions") focused on developing and seeing to commercialize nanotechnology products and applications and has funded a number of prototype development efforts in leading university labs in exchange for the right to license the technology developed in such labs.

Majority-owned Subsidiaries

Arrowhead owns a majority interest in each of its three operating Subsidiaries, securing substantial participation in any success. Each subsidiary is staffed with its own technical team that focuses on its specific technology and markets, while Arrowhead provides financial, strategic and administrative resources. The Company's majority-owned Subsidiaries seek to commercialize a variety of nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and fullerene anti-oxidants. The two companies in which Arrowhead owns minority positions are focused on developing advanced nanomaterials for spinal cord injury and wound healing and drug delivery technology. Arrowhead's business plan includes adding to its portfolio through selective acquisition and formation of new companies.

Sponsored Research

Arrowhead is taking advantage of a key trend in technology innovation. More and more in recent years, fueled by government and private funding, major new discoveries and product inventions are happening at universities rather than in the research and development divisions of large corporations. Universities are patenting and licensing these inventions through technology transfer offices, and academic researchers have become interested in commercialization of their work.

In exchange for the right to license the resultant technology developed in sponsored laboratories, Arrowhead sponsors university research. Arrowhead has worked with some of the most highly-regarded academic institutions in the country, including the California Institute of Technology ("Caltech"), Stanford University ("Stanford"), Duke University ("Duke") and the University of Florida ("UF"), in critical areas such as stem cell research, carbon electronics and molecular diagnostics.

Subsidiaries

At June 30, 2008, the Company had three majority-owned operating Subsidiaries:
Calando Pharmaceuticals, Inc. ("Calando"), which is the combined corporation that resulted from a merger of the Company's two majority owned subsidiaries, Insert Therapeutics, Inc. ("Insert") and Calando Pharmaceuticals, Inc.), Unidym, Inc. ("Unidym", formerly NanoPolaris, Inc.) and Tego BioSciences Corporation ("Tego"). Aonex Technologies, Inc. ("Aonex") was sold in May 2008. As part of its business model, the Company will create subsidiaries to commercialize promising technologies or close subsidiaries based upon lack of progress of the Subsidiary. The success of our Subsidiaries is subject to many risk factors, including technology and product acceptance and maintenance of intellectual property rights. The following discussion is qualified by the risk factors under the caption "Risk Factors" in this report and our most recent Annual Report on Form 10-K filed with the SEC.

Calando Pharmaceuticals, Inc.

On April 17, 2008, Insert Therapeutics, Inc. and Calando Pharmaceuticals, Inc. completed a merger that was the final step in a process to bring the management of Insert and Calando to the Arrowhead level to take advantage of newly hired expertise in nanobiotechnology. Insert Therapeutics, Inc. was the surviving corporation changed its name to "Calando Pharmaceuticals, Inc." The corporation formerly known as Calando Pharmaceuticals, Inc. was dissolved by action of the merger. The merger also combined the two complementary technologies and streamlined the operations of the two companies.

siRNA Delivery

Calando is continuing the development begun at the corporation formerly known as Calando Pharmaceuticals, Inc. (now dissolved by action of the merger) of novel RNAi therapeutics to treat diseases and other medical conditions by combining effective RNAi therapeutics with patented and proprietary delivery technologies. The system is designed to be used to systemically deliver any siRNA. Calando's therapeutic candidate, CALAA-01, is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target, and Calando's proprietary siRNA polymer delivery system. In March 2008, Calando filed an IND application for a Phase I trial of CALAA-01. The trial commenced in May 2008 at the South Texas Accelerated Research Therapeutics (START) clinic in San Antonio, Texas. The trial will also be conducted at the UCLA Jonsson Cancer Center (UCLA) in Los Angeles, California. The Phase I study is an open-label, dose-escalation clinical trial in patients with non-resectable or metastatic solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of CALAA-01 in humans. Additional objectives include characterization of pharmacokinetics, evaluation of tumor response, and recommendation of a CALAA-01 dose for future clinical studies.

Small Molecule Drug Delivery

Calando is continuing the development of Cyclosert�, a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers begun when the corporation was known as Insert Therapeutics, Inc. IT-101 is a conjugate of Calando's patented nano-engineered drug delivery polymer and Camptothecin, a potent anti-cancer compound. A Phase I study for IT-101 began in the summer of 2006 at the City of Hope Cancer Center. Interim results from the trial were reported in June 2007. The report, though not conclusive, was consistent with promising efficacy. In general, IT-101 was well tolerated and pancytopenia was the dose limiting toxicity. Pharmacokinetics data were favorable and consistent with results from preclinical animal studies. In patients studied, IT-101 showed longer half life, lower clearance and lower volume of distribution than seen in patients treated with other Camptothecin-based drugs. The Phase I trial is expected to be completed in 2008. In April 2008, Calando filed a second IND with the FDA to commence a Phase II trial in patients with ovarian cancer. The Phase II study is designed to demonstrate prolonged time until disease progression in patients who achieved a response or stabilization in their disease following a second line course of platinum-based chemotherapy. Previous work with IT-101 suggests that protracted "maintenance doses" of IT-101 may minimize the typical chemotherapy side effects, allow for an improved quality of life while continuing treatment, and prolong time until disease progression. The company plans to begin dosing patients later this year.

Unidym

Unidym is developing high-performance, cost-effective carbon nanotube-based products for the electronics industry. Through license of intellectual property from several universities and by virtue of its April 2007 merger with Texas-based Carbon Nanotechnologies, Inc. ("CNI"), Unidym has assembled exclusive commercial rights related to carbon nanotube manufacture and applications. The merger also provided Unidym with the ability to manufacture carbon nanotubes on a larger scale. Unidym's initial product is a transparent conductive film designed to replace the expensive and brittle metal oxide films currently used in electronic products like flat panel displays, touch screens, OLEDs and thin film solar cells. In addition to its product development efforts, Unidym manufactures and sells carbon nanotubes to customers and has entered into joint development agreements to incorporate its carbon nanotube films into existing products.

Tego

Tego Biosciences, Inc. is developing pharmaceuticals based on the unique biochemical properties of modified fullerenes. Along with the on-going studies with the National Cancer Institute and university laboratories, Tego has initiated a number of pre-clinical studies to better understand the chemistry and the pharmacology as well as the efficacy and potency of its proprietary fullerene based compounds. The studies include applications in the areas of magnetic resonance imaging contrast agents and ophthalmic therapeutics.

Minority Investments in Private Companies

Nanotope, Inc.

Nanotope, Inc. ("Nanotope") is developing advanced nanomaterials for the treatment of spinal cord injuries and wound healing. Nanotope is based on technology developed in the laboratories of Dr. Samuel Stupp at Northwestern University. Nanotope's lead product is a compound that when injected or applied at a wound site self-assembles to form a scaffold of nanofibers on which cells can grow and differentiate to heal the wound.

Leonardo Biosystems, Inc.

Leonardo Biosystems, Inc. ("LBS") is developing a drug-delivery platform technology that is based on novel methods of designing spheroid porous silicon microparticles that selectively accumulate in the tumor vasculature. The microparticles are designed to be loaded with drug associated nanoparticles. LBS is based on technology developed in the University of Texas laboratory of Dr. Mauro Ferrari.

Nanotope and LBS were both co-founded by Dr. Anzalone through the Benet Group. Dr. Anzalone is the sole owner of and manager of the Benet Group. Through the Benet Group, Dr. Anzalone owns 1,395,900 shares of Nanotope common stock and 918,750 shares of LBS' common stock, or approximately 14.2% (after giving effect to the sale of Nanotope Series B Preferred Stock) and approximately 18.4% of each Company's outstanding voting securities, respectively. Dr. Anzalone does not hold options, warrants or any other rights to acquire securities of Nanotope or LBS, directly or through the Benet Group. The Benet Group has the right to appoint a representative to the boards of directors of each of Nanotope and LBS. Dr. Anzalone currently serves on the Nanotope board in a seat reserved for Nanotope's CEO and another individual holds the seat designated by the Benet Group. Dr. Anzalone serves on the LBS board as the designee of the Benet Group. Dr. Anzalone has served as CEO and President of both companies since their formation and continues to serve in these capacities. Dr. Anzalone has not received any compensation for his work on behalf of either Nanotope or LBS since joining the Company on December 1, 2007. Dr. Anzalone has also waived his right to any unpaid compensation accrued for work done on behalf of these companies before he joined the Company.

Discontinued Operations

On May 6, 2008, a merger was completed pursuant to an Agreement and Plan of Merger by and among Aonex and AmberWave Systems Corporation, a Delaware corporation in the business of research, development and licensing of advanced technologies for semiconductor manufacturing and Aonex Acquisition Corporation a California corporation and wholly-owned subsidiary of the AmberWave formed for the purpose of acquiring Aonex's business.

At the effective time of the merger, Arrowhead received $450,000 in immediate consideration. Depending upon Aonex's subsequent performance, the former stockholders of Aonex are eligible to receive up to $7.95 million and a potential royalty for solar applications of Aonex technology. As a former holder of preferred stock in Aonex, Arrowhead will receive the first $6,298,000. Any amounts in excess of $6,298,000 will be paid on a pro rata basis, with 64% of such payments, if any, made to Arrowhead and 36% of such payments, if any, to the former holders of Common Stock of Aonex. For further information, see Note 5, Discontinued Operations, to our Consolidated Financial Statements, which summarizes the various criteria for the Earn-out Payments.

Critical Accounting Policies and Estimates

Management makes certain judgments and uses certain estimates and assumptions when applying accounting principles generally accepted in the United States in the preparation of our Consolidated Financial Statements. We evaluate our estimates and judgments on an on-going basis and base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances. Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what we anticipate and different assumptions or estimates about the future could change our reported results. We believe the following accounting policies are the most critical to us, in that they are important to the portrayal of our consolidated financial statements and require our most difficult, subjective or complex judgments in the preparation of our consolidated financial statements. For further information, see Note 1, Organization and Significant Accounting Policies, to our Consolidated Financial Statements, which outlines our application of significant accounting policies and new accounting standards.

Revenue Recognition

Revenue from product sales is recorded when persuasive evidence exists that an arrangement existed, title had passed and delivery has occurred, the price was fixed and determinable, and collection is reasonably assured.

We may generate revenue from product sales, technology licenses, collaborative research and development arrangements, and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding, and various milestone and future product royalty or profit-sharing payments.

Revenue associated with up-front license fees and research and development funding payments, under collaborative agreements, is recognized ratably over the relevant periods specified in the agreement, generally the research and development period. Revenue from substantive milestones and future product royalties is recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Payments received in advance of recognition as revenue are recorded as deferred revenue.

Research and Development Expenses

Research and development expenses include salaries and benefits, trial (including pre-clinical, clinical and other) and manufacturing costs, purchased in-process research expenses, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaborative research and development. Research and development costs are expensed as incurred.

Impairment of Long-lived Assets

We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that our assumptions about the useful lives of these assets are no longer appropriate. If an impairment is indicated, the asset is written down to its estimated fair value based on quoted fair market values.

Intellectual Property

Intellectual property consists of patents and patent applications internally developed, licensed from universities or other third parties or obtained through acquisition. Patents and patent applications are reviewed for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable, and any impairment found is written off. Licensed or internally developed patents are written off over the life of the patent unless impairment occurs. Purchased patents are written off over three years, unless an impairment occurs sooner.

Results of Operations

The Company had a consolidated net loss of approximately $7,502,000 and $18,431,000 for the three-month and nine-month periods ended June 30, 2008, respectively, versus a consolidated net loss of $12,478,000 and $22,359,000 during the same three-month and nine-month periods in the prior year. The smaller 2008 loss is primarily the result of the 2007 charge of $9,597,000 to purchased in-process research and development resulting from the April 2007 acquisition of CNI by Unidym. In fiscal 2007, Calando also incurred additional expenses attributable to its Phase I clinical trail of the IT-101 and preparing for Phase II. In 2007, Calando was also aggressively pursuing the manufacture of its drug candidate and preparations to file its IND for CALAA-01. In the current year, the reduction in expenses at Calando are offset by increases at Unidym associated with the increase in R&D activities, including operations in Houston added with the merger with CNI in April 2007. Income from grants and carbon nanotube sales at Unidym also offset the consolidated net loss for current versus the prior periods.

Revenues

The Company generated revenues of $235,000 and $623,000 for the three months ended June 30, 2008 and 2007, respectively, and revenues of $1,363,000 and $630,000 for the nine months ended June 30, 2008 and 2007, respectively. The revenue for the three months ended June 30, 2008 consists of $85,000 from license fees from Unidym technology, $144,000 from the sale and delivery of carbon nanotubes to third parties and $6,000 for shipping charges. The revenue for the first nine months of fiscal 2008 consists of $748,000 from grants to fund research for the development of carbon nanotube applications, $507,000 from the sale and delivery of carbon nanotubes to third parties and $23,000 for shipping charges. The $630,000 of revenue in the prior year's nine-month period consisted of $409,000 from grants to fund research for the development of carbon nanotube applications, $207,000 from the sale and delivery of carbon nanotubes to third parties, $7,000 for shipping charges and $7,000 of revenue from a National Institute of Health grant at Calando.

Operating Expenses

Three Months ended June 30, 2008 and 2007

The Company had operating expenses of $9.97 million during the three months ended June 30, 2008, compared to $17.67 million in the same three months in the prior year. The prior year quarter includes a $9,597,000 charge to purchased in-process R & D for the CNI acquisition.

Excluding the purchased in-process R & D charges, total operating expenses increased period over period and year over year. The composition of those expenses changed. The Company has significantly expanded its Unidym operations and headcount, adding locations in Menlo Park, California, and through the acquisition of CNI in April of 2007, in Houston, Texas. Increases in current year salary related costs were offset by reductions in outside laboratory and contract services as Calando completed the manufacture of drug candidates and streamlined operations. Calando has multiple clinical trials in process whereas in 2007, the expenses incurred were in preparation for those trials.

The Phase I and Phase II clinical trials of Calando's drug IT-101 continue. Calando also completed the process of preparing its IND Application for its CALAA-01 drug candidate and received approval to dose its first patient. Calando's Phase I trial for CALAA-01 began in May 2008 with the dosing of the first patient.

The Company added scientific and executive employees increasing its full-time head count by approximately 20 since the same period in the prior year. Unidym's head count increased by approximately 30 full-time employees. In anticipation of the merger and change in management of Insert and Calando, and the resulting duplication, the combined headcount was reduced by 10 full-time employees. Year over year increases in each major revenue and expense category are the result of the acquisition of CNI by Unidym in April 2007 and operations and the continuing clinical trials by Calando, and the hiring of additional scientific and administrative personnel at the Subsidiaries.

For purposes of comparison, the amounts for the three-month and nine-month periods ended June 30, 2008 and 2007, respectively, are shown in the tables below. Prior period amounts have been reclassified to conform to the current period presentation. Historical amounts have been adjusted to eliminate any Aonex related activities as a result of its sale in May 2008. Aonex is now reflected as Discontinued Operations in the financial statements. The amounts for each period have been adjusted to include the adoption of SFAS 123R.

Nine months ended June 30, 2008 and 2007

The net loss for the nine months ended June 30, 2008 was approximately $18.43 million compared to a loss of approximately $22.36 million for the same period last year. The loss for the first nine months of fiscal 2008 includes significant increases in headcount resulting from the acquisition of CNI and the scaling up of Unidym's administrative, research and manufacturing operation. Non-cash charges included $2.57 million related to stock based compensation, $850,000 related to the depreciation of equipment and amortization of patents and $136,000 resulting from a gift of Arrowhead stock to Rice University. Other major expense categories for the current period are $10.03 million for payroll and related expenses, $2.17 million in consulting expenses, $4.90 million in general and administrative expenses and $6.51 million in research and development expenses. For the comparable period in the prior year, the Company incurred $6.12 million in payroll and related expenses, $1.24 million in consulting expenses, $3.85 million in general and administrative expenses and $17.57 million in research and development expenses. The increase in salaries and related expenses is related to the hiring of a CEO, Chief Patent Officer, a Vice President, Advanced Materials and a Vice President, Medical Technologies at Arrowhead and the 25 additional management, administrative staff and technical staff at Unidym. The increase in consulting expense is the result of an increase in the clinical consulting at Calando, associated with the preparation of the IND application and the administration of the clinical trials. Unidym has employed consultants to assist with the development of the thin film manufacturing process. After adjusting for the CNI acquisition in 2007, the decrease in R&D expense compared to the prior year is related to the significant prior year costs for the preclinical studies, process development and manufacture of the drug candidates, and the preparations for Phase I clinical trials for CALAA-01 and Phase II clinical trials for IT-101, as well as process development for Unidym's first product and the establishment of lab facilities for Unidym in Menlo Park.

Salary & Wage Expenses

The Company employs management, administrative and technical staff at the Arrowhead corporate offices and at the Subsidiaries. Salary and wage expense consists of salary, benefits, and non-cash charges related to stock based compensation in the form of stock options. Salary and benefits can be divided into three major categories: general and administrative compensation-related expenses, stock-based compensation expense, and research and development (R&D) compensation-related expenses, depending on the primary activities of each employee. The following table details salary and related expenses for the three-month and nine-month periods ended June 30, 2008 and 2007.

For the three months ended June 30, 2008 and June 30, 2007

(in thousands)

Three Months % of Three Months % of Increase (Decrease)
Ended Expense Ended Expense
June 30, 2008 Category June 30, 2007 Category $ %
G&A - compensation-related $ 1,511 39 % $ 1,136 44 % $ 375 33 %
Stock-based compensation $ 1,029 26 % $ 527 20 % $ 502 95 %
R&D - compensation-related $ 1,357 35 % $ 921 36 % $ 436 47 %

Total $ 3,897 100 % $ 2,584 100 % $ 1,313 51 %


For the nine months ended June 30, 2008 and June 30, 2007

(in thousands)

Nine Months % of Nine Months % of Increase (Decrease)
Ended Expense Ended Expense
June 30, 2008 Category June 30, 2007 Category $ %
G&A - compensation-related $ 4,030 40 % $ 2,445 40 % $ 1,585 65 %
Stock-based compensation $ 2,570 26 % $ 1,492 24 % $ 1,078 72 %
R&D - compensation-related $ 3,429 34 % $ 2,182 36 % $ 1,247 57 %

Total $ 10,029 100 % $ 6,119 100 % $ 3,910 64 %


General and Administrative (G&A) compensation expense increased in the three month and nine months ended June 30, 2008, compared to the same periods in 2007 due to the hiring of several new positions. New positions hired included Chief Executive Officers at Arrowhead (December 2007), Unidym (June 2007) and Calando . . .

[Scar]

letztlich machen die immer noch große Verluste.
Stellt sich die Frage wie lange das noch so weitergeht und ob irgendwann das Geld ausgeht.
Kenne mich auf dem Gebiet zu wenig aus, als daß ich sagen kann, es wäre normal. Vielleicht kann jmd seine Einschätzung dazu abgeben.

[Scar]

Antwort auf Beitrag Nr.: 34.712.087 von Scar am 12.08.08 19:57:03

die Aktie wurde noch vor kurzem von einigen Börsenzeitungen in den Himmel gelobt, zwar spekulativ aber mit sehr guten Aussichten. Wenn sich nun doch noch alles ins Positive wendet, geht es da gleich auf locker mehr 4 eur. Hoffen wir das beste. Ist halt ein Langfristinvestment und am Ende könnte es noch ne schöne Sache weden

[Scar]

Antwort auf Beitrag Nr.: 35.036.180 von Scar am 09.09.08 14:35:13

ist hier niemand mehr an Board?

[eyeq69]

Antwort auf Beitrag Nr.: 35.254.709 von Scar am 24.09.08 16:04:19

doch und kaufe stetig nach :-)

[Bronto99]

Antwort auf Beitrag Nr.: 35.493.204 von eyeq69 am 09.10.08 12:11:12

Recht hast Du, CNT und siRNA Schwergewichte für 30 Mio USD. Den meisten von uns hat die derzeitige Krise derart die Sicht vernebelt, dass das noch wenige wahrnehmen.
Das ist ein sehr guter Deal, egal ob es die Aktien noch billiger geben sollte.

[Scar]

Antwort auf Beitrag Nr.: 35.494.632 von Bronto99 am 09.10.08 13:40:18

was ist CNT und siRNA ?

[Bronto99]

Antwort auf Beitrag Nr.: 35.499.936 von Scar am 09.10.08 18:42:04

Unidym ist führend im Bereich CNT=carbon nano tube.
Calando ist führend im Bereich siRNA=small interfering Ribonukleinsäure

[Scar]

Antwort auf Beitrag Nr.: 35.500.639 von Bronto99 am 09.10.08 19:27:43

alles klar, danke für die Info

[eyeq69]

Antwort auf Beitrag Nr.: 35.494.632 von Bronto99 am 09.10.08 13:40:18

ja dummerweise ist der großteil meines bestandes noch zu über 2 € gekauft worden :-(. senke jetzt meinen einstandskurs so gut es geht und dann lege ich mich schlafen :-)

[Scar]

Antwort auf Beitrag Nr.: 35.577.342 von eyeq69 am 15.10.08 13:56:17

geht mir ebenso. Bin schon seit ca. 3 Jahren dabei und war schon mehr als 100% im Plus. Will aber langfristig anlegen. DAher habe ich nicht getradet. Ich hoffe nur Arrowhead bekommt keine Probleme wg Bankenkrise, da es sicherlich schwerer wird Kredit zu bekommen.
Gerade davon dürfte Arrowhead aber auch abhängig sein.
(Reine Vermutung) Ich weiß nicht ob die Liquidität gesichert ist.

[eyeq69]

die haben ja erst im august ne kapitalerhöhung gemacht. ausserdem stand im stockholder newsletter, dass sie mit dem cash konservativ umgehen.

anbei neue meldung bezüglich cnt :-))

Unidym Announces a Demonstration by Samsung Electronics of the First Color Carbon Nanotube-Based Electrophoretic Display
MENLO PARK, Calif.--(BUSINESS WIRE)--Unidym, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today that Samsung Electronics is demonstrating the world’s first carbon nanotube-based color active matrix electrophoretic display (EPD) e-paper at the International Meeting on Information Display (iMiD) at KINTEX, Ilsan, Korea from October 13th through October 17th. The new color e-paper device is a 14.3” format display and is the result of an ongoing joint development program between Samsung Electronics Co., Ltd. and Unidym. The e-paper device uses a carbon nanotube (CNT) transparent electrode developed by Unidym.

“Our ongoing successful collaboration with Samsung Electronics has delivered yet another world’s first achievement this year,” said Arthur L. Swift, Unidym’s president and CEO. “In May of this year Samsung demonstrated the world’s first 2.3 inch black and white active matrix EPD made with carbon nanotubes, and now they have demonstrated the first color large scale EPD e-paper device, in an A4 format. This accomplishment marks a strong beginning to the second year of our joint development agreement to drive technology leadership between our companies in incorporating our carbon nanotube transparent electrodes into current display technologies.”

“This impressive accomplishment has been enabled by our continued improvement in important properties of our CNT films,” said Dr Paul Drzaic, CTO of Unidym. “To serve the various needs of the electronic display industry, our CNT materials need to demonstrate a number of key attributes: conductivity comparable to the incumbent ITO technology, uniformity over large areas in films, and compatibility with different display technologies and fabrication processes. This achievement between Samsung and Unidym demonstrates the applicability of Unidym’s CNT films in electronic displays.”

EPD’s offer inherent advantages over traditional flat panel displays due to their low power consumption and bright light readability, making them well suited for handheld and mobile applications. Since they can be produced on thin, flexible substrates, EPD’s also are ideally suited for use in e-paper applications. Unlike conventional flat panel displays, EPD’s rely on reflected light, and can retain text or images without constant refreshing, thereby dramatically reducing power consumption.

About Unidym, Inc.

Unidym is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners. As a result of its recent merger with CNI, Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications.

Unidym is focused on the electronics industry where its initial products include transparent electrodes for touch screens, flat panel displays, solar cells, and solid state lighting; electrodes for fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing a cross-industry partnership strategy to capture value from the wide ranging uses of CNTs. Unidym’s licensing program, technical expertise and manufacturing facilities can enable partners to rapidly develop CNT solutions for their specific applications.

http://www.businesswire.com/portal/site/google/?ndmViewId=ne…

[eyeq69]

Antwort auf Beitrag Nr.: 35.591.957 von eyeq69 am 16.10.08 14:45:15

hier der link zum stockholder update.

soll jetzt über die nächsten wochen regelmäßig erfolgen.

http://www.nanotech-now.com/news.cgi?story_id=30999

[Scar]

Antwort auf Beitrag Nr.: 35.591.957 von eyeq69 am 16.10.08 14:45:15

von der Kapitalerhöhung habe ich gar nichts mitbekommen.
Wurden da Bezugsrechte ausgegeben? Wohl nicht oder?

[eyeq69]

Antwort auf Beitrag Nr.: 35.596.241 von Scar am 16.10.08 21:27:43

habe ich auch erst danach mitbekommen. findest du bei den sec fillings von arrowhead. ich glaube die haben 5 millionen aktien ausgegeben die alle sofort vergriffen waren. ich glaube die wurden nur an shareholders ausgegeben.
naja aber später gabs die ja billiger, so dass ich noch mal ein paar tausend gekauft habe.

[eyeq69]

Antwort auf Beitrag Nr.: 35.599.519 von eyeq69 am 17.10.08 08:44:34

hier die news von reuters.

Arrowhead Research Corporation Completes Previously Announces Registered Direct Offering
Tuesday, 9 Sep 2008 07:00am EDT
Arrowhead Research Corporation announced that it has completed its previously announced registered direct offering, increasing total gross proceeds to approximately $6.9 million. The final closing raised an additional $2.5 million over the $4.4 million previously announced. A total of 3.9 million units consisting of common stock and common stock warrants were sold to investors, a majority of whom are either long standing shareholders or members of the Company's senior management team.


Arrowhead Research Corporation Announces $4.4 Million Investment By Current Shareholders
Tuesday, 26 Aug 2008 07:00am EDT
Arrowhead Research Corporation announced that it has sold 2.5 million units consisting of common stock and common stock purchase warrants in a registered direct offering to investors. Gross proceeds will be approximately $4.4 million. Net proceeds from this offering will help fund operations and contribute to the Company's runway to monetization events of its subsidiaries. The non-management investors purchased 2,281,990 units at a per unit price of $1.80. Each unit consisted of one share of common stock and a warrant to purchase an additional share of common stock at an exercise price of $2.00 per share. Members of the Company's senior management purchased 177,596 units at a per unit price of $1.83. The Company may sell up to an additional 3,095,968 units in follow-on offerings at $1.80 per unit (or $1.83 per unit if purchased by a Director or officer). The offering is expected to remain ongoing until September 15, 2008.

[eyeq69]

Antwort auf Beitrag Nr.: 35.599.551 von eyeq69 am 17.10.08 08:49:00

anbei der aktuelle shareholder update bezügl. calando

Arrowhead CEO Provides Update on Majority Owned Subsidiary Calando Pharmaceuticals Inc.
PASADENA, Calif. --(Business Wire)-- Arrowhead Research Corporation (NASDAQ: ARWR) announced today that the Company's CEO has provided an update letter to stockholders on its majority owned subsidiary, Calando Pharmaceuticals:

Dear Arrowhead Stockholders,

Calando Pharmaceuticals is Arrowhead's most mature biopharmaceutical subsidiary. Based on technology developed at the California Institute of Technology, Calando's proprietary linear cyclodextrin nanoparticle technology has been optimized to deliver small molecule drugs using Calando's Cyclosert(TM) system and RNAi therapeutics using the RONDEL(TM) system. Using these platform systems, Calando has developed two anti-cancer drug candidates that are currently undergoing human clinical trials.

RNA interference or RNAi is a naturally-occurring mechanism within cells that selectively silences and regulates the expression of specific genes. Many diseases are caused by the inappropriate expression of certain genes and there is significant interest within the pharmaceutical industry in using RNAi to effectively "turn down" such target genes. This would represent a potentially revolutionary new class of medicines to treat a wide range of human diseases. RNAi can be activated by delivering small interfering RNAs (siRNAs) to the cells and tissues in which gene-silencing is desired. However, given the poor pharmacokinetics and instability of naked siRNA in the bloodstream, effectively delivering siRNA molecules to a target site has been a significant technical bottleneck to the promise of RNAi therapeutics.

Calando's RONDEL system has the potential to circumvent the impasse to siRNA systemic delivery. RONDEL has been shown to protect siRNA molecules in the bloodstream, prevent significant immune response to siRNA molecules, and to effectively mediate siRNA delivery to target tissues when intravenously administered. Given the combination of the well-documented technical hurdles associated with systemic delivery of siRNA-based therapeutics, and Calando's enabling delivery technology, we believe Calando is an attractive near term acquisition target.


Calando's RONDEL-enabled siRNA-based therapeutic, CALAA-01, is currently undergoing a phase I clinical trial in patients with solid tumors at the UCLA Jonsson Cancer Center in Los Angeles, California, and at South Texas Accelerated Research Therapeutics (START) in San Antonio, Texas. CALAA-01 targets the expression of the M2 subunit of ribonucleotide reductase, a clinically validated cancer target. To our knowledge, Calando is the first and only company with a clinical stage systemic delivery system enabled siRNA therapeutic. Further, we believe CALAA-01 is also the only clinical stage siRNA therapeutic candidate for the treatment of cancer. Although this study has only recently begun, it has progressed without complications so far. Additionally, Calando is performing preclinical studies on CALAA-02, a second RONDEL-enabled anti-cancer siRNA therapeutic candidate targeting expression of the hypoxia inducible factor-2 alpha gene.

Calando's other nano-engineered polymer delivery system, Cyclosert, is designed to deliver therapeutic small molecule drugs and peptides. IT-101 is a combination of Cyclosert and Camptothecin, a potent anti-cancer therapeutic. IT-101 recently completed a phase Ia/Ib trial at City of Hope in Duarte, California. Interim phase I data was published at the 2007 Annual Meeting of the American Society for Clinical Oncology Proceedings (ASCO) (Abstract ID 32638). The interim data showed levels of progression free disease with a promising preliminary efficacy profile. The interim data also showed IT-101 to be well tolerated. An overview of the concluded complete phase Ia/Ib trial is expected to be released shortly. A peer-reviewed publication describing the trial results is expected in early 2009.

Based on encouraging phase I safety and preliminary efficacy data, IT-101 has entered into a phase II study in ovarian cancer patients. Of women who receive a second course of chemotherapy, nearly 75% will achieve some degree of disease stabilization. However, most will ultimately experience a recurrence of their cancer within 9 to 12 months after treatment. For these women, the current standard care is to "watch and wait" until disease progression occurs.

The IT-101 Phase II study utilizes a unique design intended to demonstrate prolonged time until disease progression in patients who achieved a response or stabilization in their disease following a second line course of platinum-based chemotherapy. This study is the first of its kind: there are no approved maintenance treatments following second line chemotherapy for ovarian cancer. The study expects to enroll 150 patients in the United States. Clinical sites are currently open for enrollment and have initiated the patient recruitment process. According to the World Health Organization, ovarian cancer currently affects over 90,000 women in the U.S. and other developed nations, with approximately 25,000 new cases annually in the U.S. Based on costs of other oncology maintenance therapies, we believe IT-101 represents a multi-billion dollar market opportunity.

We also believe there remains more value yet to be unlocked in the Cyclosert and RONDEL systems, as they have been demonstrated to enhance and enable the delivery of multiple pharmaceutical entities, including peptides, small molecules as well as other RNA and DNA-based oligonucleotides. For example, Calando is applying its library of Cyclosert(TM) linkers to develop new conjugate oncology therapeutics with the goal of improving the efficacy and side effect profile of generic and in-licensed compounds. Ultimately, we believe Calando is a true platform opportunity that may enable the creation of multiple new compounds.

Sincerely,
Christopher Anzalone
Chief Executive Officer

[Bronto99]

Video zu IT-101:
http://www.youtube.com/watch?v=CPzG2g-l6EA

[eyeq69]

Antwort auf Beitrag Nr.: 35.644.535 von Bronto99 am 21.10.08 17:29:44

erste ergebnisse zur phase bezügl. it-101

Unternehmensnachrichten 23.10.2008 | 13:07 Uhr Calando Pharmaceuticals Announces Completion of IT-101 Phase 1 Clinical Study

Calando Pharmaceuticals Announces Completion of IT-101 Phase 1 Clinical StudyPASADENA, Calif.CA-CALANDO-PHARMA


PASADENA, Calif.--(BUSINESS WIRE)--
Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today completion of the IT-101 Phase I clinical study conducted at City of Hope in Duarte, California. The company expects the entire study data to be published in early 2009. IT-101 is an experimental, nanoparticle therapeutic that consists of the drug camptothecin (CPT) conjugated to a cyclodextrin polymer. IT-101, the first drug candidate in Calando's proprietary CyclosertTM pipeline, has now successfully completed a Phase I trial designed to evaluate its safety, tolerability, and pharmacokinetics in patients with inoperable or metastatic tumors.

Initially, the trial utilized a weekly dosing schedule. However, because of the excellent pharmacokinetic characteristics observed for the drug, including a half-life of approximately 40 hours, a subsequent Phase Ib was conducted utilizing a twice monthly dosing schedule. The Phase Ia and Phase Ib studies are now completed, and all trial endpoints have been successfully achieved. The drug was found to be well tolerated in both the Phase Ia and Ib studies of the trial.

A high proportion of patients displayed stable disease following treatment thereby showing evidence of IT-101's cytostatic activity. This activity is consistent with several published clinical studies reporting improved outcomes when lower doses of topotecan were administered on a continuous regimen compared to traditional intermittent schedules. Topotecan is an FDA-approved a cytotoxic chemotherapeutic that is an analog of CPT.

Based on these Phase I results, Calando has initiated a multi-center Phase II clinical trial in ovarian carcinoma patients. The Phase II trial is designed to determine whether IT-101 treatment can delay disease progression in stable disease patients who have completed a standard second line course of platinum chemotherapy. The concept of providing minimally toxic cytostatic therapy following traditional cytoreductive therapy to extend progression free survival, has become a promising avenue of treatment in clinical oncology. Several cancer therapeutics are approved for cancer maintenance therapy. These drugs are increasingly being implemented by oncologists as a relatively new option for patient care, with annual revenues in excess of $ 5 billion a year.

Successful completion of the IT-101 Phase I study opens numerous avenues for its further clinical investigation. In addition to the Phase II trial in ovarian cancer, other clinical trials, including testing IT-101 in lymphoma patients, are planned.

[eyeq69]

Antwort auf Beitrag Nr.: 35.673.625 von eyeq69 am 23.10.08 13:47:59

arrowhead erwägt verkauf von calando.

Arrowhead Considering Selling Subsidiary
Calando to Cash In On Delivery By Doug Macron
Roughly six months after merging its Calando Pharmaceuticals and Insert Therapeutics subsidiaries into a single unit under the Calando name, Arrowhead Research is considering selling off the combined firm in a bid to profit from its drug-delivery technologies, a company official confirmed this week.

The official, Arrowhead’s vice president of medical technologies and Calando CEO James Hamilton, also indicated that the parent company would be willing to split up the company to separate its RNAi and non-RNAi activities as part of a sale if the terms of the deal were right.

Citing the ongoing challenges facing systemic RNAi drug delivery, Arrowhead President and CEO Christopher Anzalone said in a letter to shareholders issued this week that Calando’s Rondel siRNA-delivery technology has made the subsidiary an “attractive near-term acquisition target.”

There are “well-documented technical hurdles associated with systemic delivery of siRNA-based therapeutics,” he wrote, and “Calando’s Rondel system has the potential to circumvent the impasse to siRNA systemic delivery.”

Hamilton told RNAi News that Arrowhead has received inquiries regarding the possible sale of Calando, and that seeking an acquirer for the subsidiary is “Arrowhead’s strategy to monetize Calando as … an asset.”

“Arrowhead’s basic approach is to build subsidiaries … and exit after they are up and running” either by selling them off, floating their shares publicly, or maintaining the units as a “revenue-generating companies underneath the Arrowhead umbrella,” Hamilton explained.

Although Calando already has two drugs in the clinic, including the siRNA-based cancer therapy CALAA-01, both are only in phase I trials and therefore years away from generating revenues. At the same time, an initial public offering is unlikely given current market conditions, he noted.

Hamilton declined to comment on the existence or status of any possible negotiations that may be underway regarding the sale of Calando.

Divide and Acquire?

In weighing the possible sale of Calando, Arrowhead has put itself in a position to take advantage of a hunger for RNAi-enabling technologies among those big biopharmaceutical players that have embraced the field.

In 2007, Roche acquired Alnylam Pharmaceuticals’ Kulmbach, Germany-based subsidiary for $15 million in cash as part of a broader drug-discovery arrangement in a bid to rapidly gain RNAi expertise and jumpstart its in-house RNAi drug efforts (see RNAi News, 7/12/2007).

About a year later, Roche announced that it would buy Mirus Bio for $125 million in cash, holding onto that company’s therapeutics operations while divesting its reagents business, in a deal that was largely driven by Mirus’ know-how in nucleic acids delivery (see RNAi News, 7/24/2008).

In 2006, Merck made one of the biggest investments in RNAi when it acquired Sirna Therapeutics for $1.1 billion in cash, a move a Merck official said was based on Sirna’s RNAi intellectual property estate and expertise (see RNAi News, 11/2/2006).

Whether a company interested in Calando’s RNAi capabilities would also be willing to buy its small-molecule assets, however, is unclear. But according to Hamilton, Arrowhead is open to the idea of once again dividing the two in order to make a deal happen — if the terms are right.

Such a split “would depend on how an acquirer would want to structure a deal,” he said. Although “I wouldn’t say that it’s necessarily the strategy that [the two parts of Calando] are going to become unbundled … [such a move could hinge] on the kind of interest” expressed by a possible acquirer.

And breaking up Calando isn’t likely to be too challenging since Arrowhead already has experience separating and combining the company’s RNAi and non-RNAi activities. In addition, Calando currently maintains two separate arms of operations, one overseen by Thomas Schluep as CSO of small-molecule delivery and the other managed by Jeremy Heidel, a Calando co-founder, as CSO of oligonucleotide delivery.

Calando was founded in 2005 to advance an RNAi-delivery technology that had been under development at Insert, which had stopped working with the gene-silencing technology (see RNAi News, 2/25/2005).

As a pure-play RNAi shop, Calando advanced its lead RNAi drug, CALAA-01, to the point of a successful investigational new drug application filing (see RNAi News, 4/24/2008). After initiation of a phase I study in June, CALAA-01 became the first formulated RNAi drug to be tested in humans.

But early this year, Arrowhead announced that it had taken over management of Calando and planned to merge the company with Insert in order to streamline their operations. The merger closed in April (see RNAi News, 5/1/2008).

[Scar]

Bin begeistert wie schön Arrowhead bei hohen Umsätzen steigt und das sogar heute gegen den Trend. Da dürfte was im Busch sein

[Scar]

Antwort auf Beitrag Nr.: 35.843.479 von Scar am 05.11.08 18:48:14

Die Begeisterung hat gehalten bis heute. AUf einmal ohne Grund 20% minus.
Dachte schon der Abwärtstrend wird gebrochen.
Vielleicht kommts ja noch...

[Scar]

Wechselbad der GEfühle. Abwärtstrend ist gebrochen

[Scar]

Seit zwei Tagen scheint jemand immer wenn der Kurs sich erholt hat mit einer ORder zwischen 20.000 und 30.000 Stück in USA den Kurs zu drücken.
Heute ging er zB auf einmal von ca 1,70 auf ca 1,45 mit einer Order um die 25.000.
Will da jmd den Kurs drücken oder was ist da los?

[conplus4518]

Jahresabschluß zum 30.09.08

http://www.sec.gov/Archives/edgar/data/879407/00011931250825…

Sales:..........1,303,201
USD
Net Loss..(27,089,030) USD

Shares per 11.12.2008: 42.934.517

[Scar]

kann jemand, der sich auskennt, was zum Jahresabschluss sagen?
War er wo erwartet oder nicht?

[Scar]

Cash ist ziemlich zurückgegangen. Scheint wichtig zu werden, daß Arrowhead bald wieder Kapitalgeber findet, da die KOsten logischerweise höher sind, als die Einnahmen. Gehälter sind jedenfalls stark angestiegen. Kenn mich aber nicht aus hinsichtlich der Hintergründe und wie es zu bewerten ist...

[Scar]

Antwort auf Beitrag Nr.: 36.214.708 von Scar am 16.12.08 15:46:20

gibts was neues?

[Scar]

weiß jemand ob Arrowhead Kapitalgeber gefunden hat bzw. ob sie sich Cash beschaffen können?

[Scar]

Das Schöne bei dem Wert ist zumindest, daß der Anstieg immer mit hohen Umsätzen erfolgt. Bei niedrigen Umsätzen geben die Kurse nach.
Zumindest ein gutes Zeichen

[Scar]

Trotzdem langweilt es langsam... ganz allein hier ... und offensichtlich auch allein in der Aktie

[Scar]

Ist das der Grund für den Rückgang?
Ausschluß aus Nasdaq droht.


PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ:ARWR - News) announced today that it has received a letter from The Nasdaq Stock Market (NASDAQ) notifying the Company that, based on its Form 10-Q for the period ended December 31, 2008, Nasdaq has determined that Arrowhead’s stockholders' equity does not comply with the minimum $10,000,000 stockholders' equity requirement for continued listing on The Nasdaq Global Market. The Nasdaq notification does not effect on the listing of Arrowhead’s common stock at this time.
Related Quotes
Symbol Price Change
ARWR 0.63 -0.07
Chart for Arrowhead Research Corporation
{"s" : "arwr","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Nasdaq is reviewing Arrowhead’s eligibility for continued listing on The Nasdaq Global Market and has asked the Company to provide a specific plan to achieve and sustain compliance with all Nasdaq listing requirements by February 26, 2009. The Company intends to respond formally to the Nasdaq request for a plan on or before the deadline.

[Scar]

Verstehe allerdings nicht, warum es erst jetzt richtig runterging.
Evtl. wg der Äußerung der FÜhrungsriege von Arrowhead, wobei
das auch nicht gleich diesen Kurs rechtfertigt.

[Scar]

Antwort auf Beitrag Nr.: 36.626.041 von Scar am 21.02.09 12:09:36

kann man Arrowhead eigentlich shorten?
Laut US Board sollen einige Shorties drin sein, was natürlich einiges erklären würde...

[Scar]

super, Arrowhead bleibt an der Nasdaq

[Scar]

fast verdoppelt den letzten monat

[Bronto99]

17 Juni in Bonn: Unidym CEO Mark Tilley "The commercial path for carbon nanotube transparent conductive films"
http://www.nanomaterials09.com/speakers_electronics.php#till…

[Scar]

Antwort auf Beitrag Nr.: 37.260.435 von Bronto99 am 27.05.09 10:56:32

jetzt wollen sie wohl einen Reverse Split machen. Dem Kurs scheint es nicht zu schaden...

[Scar]

Antwort auf Beitrag Nr.: 37.993.052 von Scar am 16.09.09 17:33:58

noch jemand hier?

[Smallcappicker]

Antwort auf Beitrag Nr.: 38.396.842 von Scar am 16.11.09 18:12:59

Bin hier, aber nicht aktiv. Mir ist grad die Visitenkarte von Chris Anzalone wieder in die Finger gekommen. Deshalb hab ich mal nachgeschaut, was sich getan hat - eigentlich nichts seit September

[eyeq69]

nein du bist nicht allein :-)

[Scar]

das ist ja mal ein schöner Anstieg heute.Um mehr als 30%. Weiß jmd warum?

[eyeq69]

Antwort auf Beitrag Nr.: 39.188.998 von Scar am 22.03.10 12:10:58

vor 2 stunden kam die meldung über die clinival trials von calando bezügl. sirna und rondel.

siehe hier:

http://www.businesswire.com/portal/site/home/permalink/?ndmV…

[eyeq69]

Antwort auf Beitrag Nr.: 39.189.921 von eyeq69 am 22.03.10 14:22:25

“This breakthrough evidence provides important validation for siRNA-based therapeutics in general, as well as for our proprietary RONDEL delivery system, and for our lead siRNA therapeutic candidate, CALAA-01”

[franzisca]

Bin auch mal dabei!

[Scar]

und was bedeutet das jetzt? Wohin wird der Kurs gehen? Ist das eine Übertreibung oder nur der Anfang?

[franzisca]

Event: Update on Calando Pharmaceuticals

Date: Tuesday, March 23rd, 1:30 p.m. PT





http://www.arrowheadresearch.com/

[Scar]

es stellt sich die Frage was an dem Produkt dran ist, bei Yahoo schreiben sie von cure of cancer, aber nach dem was ich lese, haben die kein Mittel gegen Krebs entwickelt, es geht nur in die Richtung. Weiß jemand um was es genau geht und ob es sich wirklich um einen Durchbruch handelt?

[eyeq69]

Antwort auf Beitrag Nr.: 39.194.691 von Scar am 23.03.10 08:44:33

es geht wohl eher um die technology, die medikamente dort hinzubringen wo sie wirken sollen. über die nanopartikel können die wirkstoffe (proteine) direkt in die tumorzelle transportiert werden. dort zerfallen die nanopartikel und setzen den wirkstoff gezielt dort ein wo er wirken soll. die nanopartikel werden dann üner den urin ausgeschieden. die studien über dieses verfharen laufen schon über 10 jahre und 2006 gab es den nobelpreis für diese behandlungsmethode. das problem war bisher nur den wirkstoff gezielt zu transportieren und das ist calando jetzt das erste mal beim menschen gelungen.
man muss nun sehen wie sich das weiterentwickelt und weitere studien abwarten. die wahrscheinlichkeit ist aber hoch, dass sich jetzt große pharmafirmen für diese technologie interessieren und entweder calando kaufen oder über lizenzen cash rein bringen.

der artikel in der nature beschreibt das eigentlich ganz gut.

[eyeq69]

dabei geht es wohl auch nicht nur um krebs sondern auch um eine menge andere krankheiten die bisher als nicht behandelbar galten.

die krebs turmore (krebszellen) sollen somit gezielt über proteine und gene am wachstum gehindert werden (soweit ich das verstanden habe).

[Scar]

Danke, sehr verständlich erklärt. Sieht wirklich so aus, als ob das ein großer Durchbruch ist, wenn das wirklich dauerhaft und bei allen Menschen so klappen könnte. Es ist allerdings schwer abzuschätzen welcher Kurz für Arrowhead daher gerechtfertigt ist.

Von früheren Kursen bei um die 4 €, sind wir ja meilenweit entfernt. Damals war die Forschung aber noch lange nicht so weit und trotzdem wurde soviel gezahlt. Das Cash das zwischenzeitlich verbraten wurde rechtfertigt aber eigentlich keinen solchen Abschlag auf ca. 0,8€, da der eigentliche Wert des Unternehmens in der Zukunft liegt.

Ich hatte den Wert fast schon abgeschrieben, weil ich davon ausging, das denen früher oder später das Geld ausgeht...

[Bronto99]

Antwort auf Beitrag Nr.: 39.194.691 von Scar am 23.03.10 08:44:33

Gute Informationen über Technologien zu RNAi delivery findest Du in diesem Blog:
http://rnaitherapeutics.blogspot.com/

[eyeq69]

Antwort auf Beitrag Nr.: 39.196.424 von Scar am 23.03.10 12:33:38

naja die 6 € die früher waren, waren meines erachtens zum größten teil wegen unidym als marktführer in carbon nanotubes (lcd technik/ samsung).
ich bin jetzt schon knapp 5 jahre dabei und habe zeit :-)

[Scar]

in USA gehts schon wieder stark nach oben. Sind schon wieder bei 0,91 im BID. Toll

[Scar]

Antwort auf Beitrag Nr.: 39.197.194 von eyeq69 am 23.03.10 14:16:46

dann hast du ja auch schon das schöne Auf und Nieder mitgemacht.
Ist schon hart wenn man bei 5 € mit Riesengewinn verkaufen kann und dann auf einmal wieder bei 0,3 € steht.
Ich bin am 16.2.2005 mit der ersten Position bei 1,41 € eingestiegen, also auch schon 5 Jahre...

[eyeq69]

Antwort auf Beitrag Nr.: 39.197.482 von Scar am 23.03.10 14:47:54

ja habe zum glück in 2008 kräftig nachgekauft und meinen einstandskurs auf 1,13 € /stck gedrückt. bin ja jetzt fast wieder break even :-))

[Scar]

habe auch 2008 auf 1,01 € gedrückt. Hatte eigentlich 2005 vor, den Wert 10 Jahre liegen zu lassen.
Nach dem Beinahetotalverlust verleiten diese Kurse jetzt natürlich zum Verkaufen...
Würde mir aber in den A... beissen, wenn ich jetzt bei 0,9 verkaufe und das Teil in 1 Jahr wieder bei 6 € steht. Aber so ist Börse.

[eyeq69]

Antwort auf Beitrag Nr.: 39.197.617 von Scar am 23.03.10 15:01:31

ich habe noch zeit bis dezember 2020 wenn meine zinsbindungsfrist für die hütte ausläuft. spätestens dann verkaufe ich, da ist noch genug luft.

[eyeq69]

bin auf den conference call heute gespannt

[eyeq69]

Antwort auf Beitrag Nr.: 39.197.617 von Scar am 23.03.10 15:01:31

RXi Pharmaceuticals Corporation forscht auch in auf dem gebiet von rnai therapeutics, die generieren auch keine revenues und sind mit knapp 8 usd bewertet

[Scar]

Antwort auf Beitrag Nr.: 39.197.873 von eyeq69 am 23.03.10 15:29:35

Wenn du das Darlehen für den Hausbau meinst. Mein Darlehen läuft auch 2020 aus bzw. die Zinsbindung endet dann. Viele Parallelen

Weiß eigentlich jemand was für eine Marktkapitalisierung ARrowhead hat, bzw. wieviele Aktien es gibt?

[franzisca]

Antwort auf Beitrag Nr.: 39.198.072 von Scar am 23.03.10 15:47:30

http://data.cnbc.com/quotes/arwr

[Scar]

danke, mit 62,8 Mio Shares sind wir bei ca. 50 Mio MarktKap, eine doch recht hohe Summe. Frage mich nur was nun eine gerechte Bewertung ist und ob der Markt derzeit angemessen bewertet.

[eyeq69]

konnte jemand den webcast verfolgen und was sind die themen, die besprochen wurden?

hatte bisher keine zeit den, mir den webcast abzusehen.

danke und grüße
eyeq

[Scar]

Unglaublich wie schön sich die Aktie nach so langem Warten
nun entwickelt. Heute gehts schon wieder rauf...

[Scar]

Heute soll glaube ich eine Präsentation oäö stattfinden.
Deswegen ging der Kurs die letzten Tag ab.
Weiß da jemand mehr?

[Scar]

na endlich, plus 26% heute :-)

[Scar]

endlich gehts wieder nach oben

[Scar]

endlich kommt Bewegung rein

[Scar]

mittlerweile verfünfacht

[Scar]

versiebenfacht :-) und keiner kennt die Aktie hier